Tinzaparin Sodium

ApprovedSmall molecule

UUniversity of Calgary

Tinzaparin Sodium is one of 129 small molecule programs targeting Venous Thromboembolism. It is currently in Approved.

Indications

Total Trials

Active Trials

128

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

Kidney CancerActive, not recruiting

Deep Vein ThrombosisActive, not recruiting

Ischemic StrokeActive, not recruiting

Venous ThromboembolismPhase 2

Active, not recruiting

Kidney CancerPhase 1/Phase 2

Active, not recruiting

Deep Vein ThrombosisApproved

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Tinzaparin Sodium

UUniversity of Calgary

Approved

1 2

Proamatine

Takeda

Preclinical

2 3

Repatha

Amgen

Preclinical

2 4

Levaquin

WWim Janssens

Preclinical

3 5

Tylenol

KKenvue Brands

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Prophylaxis

NCT05735639

Clinical

Trials by Indication[1]

Deep Vein Thrombosis2 trials

Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin

Completed·UUniversity of Calgary·Phase 4·NCT00203658·400 enrolled

Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)

Completed·UUniversity of Calgary·Phase 4·NCT00203580·910 enrolled

Venous Thromboembolism2 trials

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

Terminated·UUniversity of Southern California·Phase 2·NCT00981903·131 enrolled

Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT03090880·59 enrolled

Ischemic stroke1 trial

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00061373·18 enrolled

Prophylaxis1 trial

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Recruiting·IImperial College London·Phase 4·NCT05735639·6,660 enrolled

Kidney Cancer1 trial

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

Unknown status·UUniversity of Vermont·Phase 1/2·NCT00293501·35 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Tinzaparin Sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tinzaparin Sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tinzaparin Sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of Calgary

Tinzaparin Sodium

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Deep Vein Thrombosis2 trials

Venous Thromboembolism2 trials

Ischemic stroke1 trial

Prophylaxis1 trial

Kidney Cancer1 trial

References

Drug Info

Quick Facts

Related News